Prostate Cancer Features

Physician Polls Has the proportion of your patients undergoing prostate brachytherapy been declining?

Has the proportion of your patients undergoing prostate brachytherapy been declining?

Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.

Men's Health Update Neglected Side Effects of Radical Prostatectomy

Neglected Side Effects of Radical Prostatectomy

A questionnaire-based study revealed significant side effects that are not commonly discussed.

Prostate Cancer Videos

Latest Prostate Cancer News

Prostate Biopsy Complication Rates Increasing

Prostate Biopsy Complication Rates Increasing

Urologic complications requiring hospital admission grew from 3.6% in 2000 to 3.9% in 2008, largely because of infections.

Radical Prostatectomy Outcomes Similar for Obese, Non-Obese

Radical Prostatectomy Outcomes Similar for Obese, Non-Obese

Outcomes of robot-assisted radical prostatectomy in obese patients are mostly comparable to non-obese patients.

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage Radiation Failure

Good Prostate Cancer (PCa) Outcomes Possible Despite Salvage Radiation Failure

Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.

Early Adjuvant Radiotherapy Benefits Selected Prostate Cancer Patients

Early Adjuvant Radiotherapy Benefits Selected Prostate Cancer Patients

Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.

Sexual Function Preserved in Prostate Cancer Combination Therapy

Sexual Function Preserved in Prostate Cancer Combination Therapy

High rates of preserved sexual function with combination beam plus brachytherapy.

Radical Prostatectomy Rates Rising

Radical Prostatectomy Rates Rising

Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.

Male Pattern Baldness Linked with Prostate Cancer

Male Pattern Baldness Linked with Prostate Cancer

Men with male pattern baldness may face a higher risk of aggressive prostate cancer.

Statins Reduce Prostate Cancer Recurrence Risk After Radiotherapy

Statins Reduce Prostate Cancer Recurrence Risk After Radiotherapy

This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.

Watchful Waiting Not Suitable for Black Men with Prostate Cancer

Watchful Waiting Not Suitable for Black Men with Prostate Cancer

Black prostate cancer patients more likely to develop aggressive disease earlier than white patients.

Aspirin Eases Genitourinary (GU) Toxicity from Prostate Cancer Radiotherapy

Aspirin Eases Genitourinary (GU) Toxicity from Prostate Cancer Radiotherapy

Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.

Genetic Variant May Predict Resistance to Prostate Cancer Drugs

Genetic Variant May Predict Resistance to Prostate Cancer Drugs

Enzalutamide and abiraterone may not benefit men with metastatic castration-resistant prostate cancer who have AR-V7 in circulating tumor cells.

Men with Metabolic Aberrations Have Lower Prostate Cancer Risk

Men with Metabolic Aberrations Have Lower Prostate Cancer Risk

However, they are more likely to die from causes other than prostate cancer than men with normal metabolic levels.

FDA Approves New Indication for Enzalutamide

FDA Approves New Indication for Enzalutamide

The drug is now also approved for use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Brachytherapy Offers Favorable Long-Term Prostate Cancer Survival

Brachytherapy Offers Favorable Long-Term Prostate Cancer Survival

Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.

AR-V7 Cells Tied to Chemo Resistance in Prostate Cancer

AR-V7 Cells Tied to Chemo Resistance in Prostate Cancer

Detection of AR-V7 in circulating tumor cells linked to enzalutamide and abiraterone resistance.